Answers are grounded in this paper and cite their sources.
Disproportionality analysis reports real-world adverse events associated with palbociclib in post-marketing surveillance, highlighting emerging drug safety concerns.
Objectives To explore the association between palbociclib and related adverse events (AEs) in the real world through U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: